Article Dans Une Revue (Article De Synthèse) OncoTargets and Therapy Année : 2019

Update on elotuzumab for the treatment of relapsed/refractory multiple myeloma: patients’ selection and perspective

Résumé

Monoclonal antibodies (mAbs) targeting antigens expressed by plasma cells demonstrated major clinical activity in multiple myeloma patients and therefore became a new major class of drug for these patients. Elotuzumab is a humanized mAb targeting the cell surface signaling lymphocytic activation molecule family member 7, a glycoprotein highly expressed on plasma cells, that is the second mAb approved for the treatment of myeloma patients. The mechanism of action of elotuzumab includes natural killer cell (NK) mediated antibody-dependent cellular cytotoxicity and direct activation of NK-cells. Elotuzumab has been approved in combination with lenalidomide and dexamethasone (Elo-Rd) and pomalidomide and dexamethasone (Elo-Pd) for the treatment of relapsed myeloma patients. The present review will focus on elotuzumab, providing a summary of the mechanism of action, efficacy and safety and taking into consideration patients' selection.
Fichier principal
Vignette du fichier
ott-12-5813.pdf (275) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte
licence

Dates et versions

hal-04960337 , version 1 (21-02-2025)

Licence

Identifiants

Citer

Sabrina Trudel, Philippe Moreau, Cyrille Touzeau. Update on elotuzumab for the treatment of relapsed/refractory multiple myeloma: patients’ selection and perspective. OncoTargets and Therapy, 2019, 12, pp.5813 - 5822. ⟨10.2147/ott.s174640⟩. ⟨hal-04960337⟩
0 Consultations
0 Téléchargements

Altmetric

Partager

More